

# International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,<sup>1</sup> notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, e.g., for List 57 Prop. INN not later than 31 October 1987.

*The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.*


## Proposed International Nonproprietary Names (Prop. INN): List 57<sup>2</sup>

Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number

adibendanum  
adibendan

5,7-dihydro-7,7-dimethyl-2-(4-pyridyl)pyrrolo[2,3-f]benzimidazol-6(3H)-one  
C<sub>16</sub>H<sub>14</sub>N<sub>4</sub>O 100510-33-6



Comprehensive information on the INN programme can be found in: WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*, Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 (price: Sw. fr. 6.-); an account of this publication will be found in Annex 2 of the present List. All names from Lists 1-47 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in: *International Nonproprietary Names (INN) for Pharmaceutical Substances. Cumulative List No. 6, 1982*, World Health Organization, Geneva (ISBN 92 4 656013 0) (price: Sw. fr. 55.-). This publication consists, in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN)—in Latin, English, French, Russian, and Spanish—published up to April 1982. The printout also indicates in which of the 47 individual lists of proposed names and 21 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulae and Chemical Abstracts Service registry numbers. For easy reference, national nonproprietary names that differ from INN, molecular formulae, and Chemical Abstracts Service registry numbers are indexed in a series of annexes. A final annex describes the procedure for selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French.


These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of *WHO Drug Information*. Orders from countries where sales agents have not yet been appointed may be addressed to: World Health Organization, Distribution and Sales Service, 1211 Geneva 27, Switzerland.

<sup>1</sup> See Annex 1.

<sup>2</sup> Other lists of proposed and recommended international nonproprietary names can be found in *Cumulative List No. 6, 1982*.


aloxistatinum  
aloxistatin

ethyl (+)-(2*S*,3*S*)-2,3-epoxy-*N*-[(*S*)-1-(isopentylcarbamoyl)-3-methylbutyl]succinamate  
C<sub>17</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub> 88321-09-9




anaritidum  
anaritide

L-arginyl-L-seryl-L-seryl-L-cysteinyl-L-phenylalanyl-glycyl-glycyl-L-arginyl-L-methionyl-L-aspartyl-L-arginyl-L-isoleucyl-glycyl-L-alanyl-L-glutamyl-L-seryl-glycyl-L-leucyl-glycyl-L-cysteinyl-L-asparaginyl-L-seryl-L-phenylalanyl-L-arginyl-L-tyrosine cyclic (4→20)-disulfide  
C<sub>112</sub>H<sub>175</sub>N<sub>39</sub>O<sub>35</sub>S<sub>3</sub> 95896-08-5




argatrobanum  
argatroban

(2*R*,4*R*)-4-methyl-1-[(*S*)-*N*<sup>2</sup>-[[(*R**S*)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl]-sulfonyl]arginyl]pipercolic acid  
C<sub>23</sub>H<sub>36</sub>N<sub>6</sub>O<sub>5</sub>S 74863-84-6




bemarinonum  
bemarinone

5,6-dimethoxy-4-methyl-2(1*H*)-quinazolinone  
C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub> 92210-43-0




benexatum  
benexate

benzyl salicylate, *trans*-4-(guanidinomethyl)cyclohexanecarboxylate  
C<sub>23</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub> 78718-52-2




bepetidii iodidum  
bepetidum iodide

*cis*-1-ethyl-4-hydroxy-1-methylpiperidinium iodide (±)-*a*-(hexahydro-1*H*-azepin-1-yl)-1,2-benzisoxazole-3-acetate, mixture with *trans*-1-ethyl-4-hydroxy-1-methylpiperidinium iodide (±)-*a*-(hexahydro-1*H*-azepin-1-yl)-1,2-benzisoxazole-3-acetate (1:1)  
C<sub>23</sub>H<sub>34</sub>I<sub>N</sub><sub>3</sub>O<sub>3</sub> 86434-57-3




bermoprofenum  
bermoprofen

(±)-10,11-dihydro-*a*,8-dimethyl-11-oxodibenz[*b*,*f*]oxepin-2-acetic acid  
C<sub>18</sub>H<sub>16</sub>O<sub>4</sub> 72619-34-2




bifeprofenum  
bifeprofen

(±)-2'-chloro-*a*-methyl-4-biphenylacetic acid, ester with 1-glycoloyl-4-methylpiperazine  
C<sub>22</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>3</sub> 108210-73-7




bisfentidinum  
bisfentidine

*N*-isopropyl-*N'*-[*p*-(2-methylimidazol-4-yl)phenyl]formamidine  
C<sub>14</sub>H<sub>18</sub>N<sub>4</sub> 96153-56-9




cefepimum  
cefepime

1-[[[(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl-1-methylpyrrolidinium hydroxide, inner salt, 7<sup>2</sup>-(*Z*)-(O-methyloxime)]  
C<sub>19</sub>H<sub>24</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> 88040-23-7




cefmepeidii chloridum  
cefmepeidum chloride

4-[[[(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]thio]-1-methylpyridinium chloride  
7<sup>2</sup>-(*Z*)-[O-(1-carboxy-1-methylethyl)oxime] *S*-oxide  
C<sub>23</sub>H<sub>25</sub>ClN<sub>6</sub>O<sub>6</sub>S<sub>3</sub> 107452-79-9




cefepodoximum  
cefepodoxime

(±)-1-hydroxyethyl (+)-(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, 7<sup>2</sup>-(*Z*)-(O-methyloxime), isopropyl carbonate (ester)  
C<sub>21</sub>H<sub>27</sub>N<sub>5</sub>O<sub>9</sub>S<sub>2</sub> 87239-81-4




clopidogrelum  
clopidogrel

methyl (±)-*α*-(*o*-chlorophenyl)-6,7-dihydrothieno[3,2-*c*]pyridine-5(4*H*)-acetate  
C<sub>16</sub>H<sub>16</sub>ClNO<sub>2</sub>S 94188-84-8




daltrobanum  
daltroban

[*p*-2-(*p*-chlorobenzenesulfonamido)ethyl]phenyl]acetic acid  
C<sub>16</sub>H<sub>16</sub>ClNO<sub>4</sub>S 79094-20-5




datelliptii chloridum  
datelliptium chloride

2-[2-(diethylamino)ethyl]-9-hydroxy-5,11-dimethyl-6H-pyrido[4,3-b]-  
carbazolium chloride  
C<sub>23</sub>H<sub>28</sub>ClN<sub>3</sub>O 105118-14-7




dexamethasoni acefuras  
dexamethasone acefurate

9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 21-  
acetate 17-(2-fuorate)  
C<sub>29</sub>H<sub>33</sub>FO<sub>8</sub> 83880-70-0




dobupridum  
dobupride

4-amino-2-butoxy-5-chloro-N-[1-(1,3-dioxolan-2-ylmethyl)-4-piperidyl]benz-  
amide  
C<sub>20</sub>H<sub>30</sub>ClN<sub>3</sub>O<sub>4</sub> 106707-51-1




dramedilolum  
dramedilol

acetone (±)-[6-[3-[(3,4-dimethoxyphenethyl)amino]-2-hydroxypropoxy]-3-  
pyridazinyl]hydrazone  
C<sub>20</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub> 76953-65-6




droxidopa  
droxidopa

(-)-*threo*-3-(3,4-dihydroxyphenyl)-L-serine  
C<sub>9</sub>H<sub>11</sub>NO<sub>5</sub> 23651-95-8




ebrotidinum  
ebrotidine

*p*-bromo-*N*-[[[2-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]-thio]ethyl]amino]methylene]benzenesulfonamide  
C<sub>14</sub>H<sub>17</sub>BrN<sub>6</sub>O<sub>2</sub>S<sub>3</sub> 100981-43-9




eltoprazinum  
eltoprazine

1-(1,4-benzodioxan-5-yl)piperazine  
C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> 98224-03-4




elziverinum  
elziverine

6,7-dimethoxy-4-[[4-(*o*-methoxyphenyl)-1-piperazinyl]methyl]-1-veratrylisoquinoline  
C<sub>32</sub>H<sub>37</sub>N<sub>3</sub>O<sub>5</sub> 95520-81-3




eprovaferum  
eprovaferen

5-(3-phenylpropyl)-2-thiophenevaleric acid  
C<sub>18</sub>H<sub>22</sub>O<sub>2</sub>S 101335-99-3




epsiprantelum  
epsiprantel

(±)-2-(cyclohexylcarbonyl)-2,3,6,7,8,12b-hexahydropyrazino[2,1-a][2]benzazepin-4(1*H*)-one  
C<sub>20</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub> 98123-83-2




etanidazolium  
etanidazole

*N*-(2-hydroxyethyl)-2-nitroimidazole-1-acetamide  
C<sub>7</sub>H<sub>10</sub>N<sub>4</sub>O<sub>4</sub> 22668-01-5




etofenproxum  
etofenprox

$\alpha$ -[(*p*-ethoxy- $\beta$ , $\beta$ -dimethylphenethyl)oxy]-*m*-phenoxytoluene  
C<sub>25</sub>H<sub>28</sub>O<sub>3</sub> 80844-07-1




exametazimum  
exametazime

(±)-(3*RS*, 3'*RS*)-3,3'-[(2,2-dimethyltrimethylene)diimino]di-2-butanone  
dioxime  
C<sub>13</sub>H<sub>28</sub>N<sub>4</sub>O<sub>2</sub> 105613-48-7




fotemustinum  
fotemustine

(±)-diethyl [1-[3-(2-chloroethyl)-3-nitrosoureido]ethyl]phosphonate  
C<sub>9</sub>H<sub>19</sub>ClN<sub>3</sub>O<sub>5</sub>P 92118-27-9




guaisteinum  
guaisteine

thioacetic acid, *S*-ester with (±)-3-(mercaptoacetyl)-2-[(*o*-methoxyphenoxy)methyl]thiazolidine  
C<sub>15</sub>H<sub>19</sub>NO<sub>4</sub>S<sub>2</sub> 103181-72-2




ibacitabinum  
ibacitabine

2'-deoxy-5-iodocytidine  
 $C_9H_{12}IN_3O_4$  611-53-0




indolidanum  
indolidan

3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2-indolinone  
 $C_{14}H_{15}N_3O_2$  100643-96-7




iobenguanum (<sup>131</sup>I)  
iobenguane (<sup>131</sup>I)

(*m*-iodo-<sup>131</sup>I-benzyl)guanidine  
 $C_8H_{10}^{131}IN_3$  77679-27-7




lacidipinum  
lacidipine

4-[*o*-[(*E*)-2-carboxyvinyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridine-  
dicarboxylic acid, 4-*tert*-butyl diethyl ester  
 $C_{26}H_{33}NO_6$  103980-78-4




levocarnitinum  
levocarnitine

(L-3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt  
 $C_7H_{15}NO_3$  541-15-1




levofenfluraminum  
levofenfluramine

(-)-(R)-N-ethyl- $\alpha$ -methyl-*m*-(trifluoromethyl)phenethylamine  
C<sub>12</sub>H<sub>16</sub>F<sub>3</sub>N 37577-24-5




lixazinonum  
lixazinone

N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazolin-7-yl)oxy]butyramide  
C<sub>21</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub> 94192-59-3




lodaxaprinum  
lodaxaprine

1-[6-(*o*-chlorophenyl)-3-pyridazinyl]-4-piperidinol  
C<sub>15</sub>H<sub>16</sub>ClN<sub>3</sub>O 93181-81-8




loperamidum oxidum  
loperamide oxide

*trans*-4-(*p*-chlorophenyl)-4-hydroxy-*N,N*-dimethyl- $\alpha,\alpha$ -diphenyl-1-piperidinebutyramide 1-oxide  
C<sub>29</sub>H<sub>33</sub>ClN<sub>2</sub>O<sub>3</sub> 106900-12-3




lorcinadolum  
lorcinadol

(*E*)-3-chloro-6-(4-cinnamyl-1-piperazinyl)pyridazine  
C<sub>17</sub>H<sub>19</sub>ClN<sub>4</sub> 104719-71-3




lovastatinum  
lovastatin

(*S*)-2-methylbutyric acid, 8-ester with (4*R*,6*R*)-6-[2-[(1*S*,2*S*,6*R*,8*S*,8*aR*)-1,2,6,7,8,8*a*-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2*H*-pyran-2-one  
C<sub>24</sub>H<sub>36</sub>O<sub>5</sub> 75330-75-5




loxiglumidum  
loxiglumide

(±)-4-(3,4-dichlorobenzamido)-*N*-(3-methoxypropyl)-*N*-pentylglutamic acid  
C<sub>21</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>5</sub> 107097-80-3




mafoprazinum  
mafoprazine

4'-[3-[4-(*o*-fluorophenyl)-1-piperazinyl]propoxy]-*m*-acetanisidide  
C<sub>22</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>3</sub> 80428-29-1




midaglizolum  
midaglizole

(±)-2-[α-(2-imidazolylmethyl)benzyl]pyridine  
C<sub>16</sub>H<sub>17</sub>N<sub>3</sub> 66529-17-7




molfarnatum  
molfarnate

3,7,11-trimethyl-2,6,10-dodecatrienyl 4,8,12-trimethyl-3,7,11-tridecatrienoate  
C<sub>31</sub>H<sub>50</sub>O<sub>2</sub> 83689-23-0




niguldipinum  
niguldipine

(±)-3-(4,4-diphenylpiperidino)propyl methyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate  
C<sub>36</sub>H<sub>39</sub>N<sub>3</sub>O<sub>6</sub> 102993-22-6




nuclomedonum  
nuclomedone

(±)-6-(*p*-chlorobenzyl)-2,3-dihydro-5*H*-thiazolo[3,2-*a*]pyrimidine-5,7(6*H*)-dione  
C<sub>13</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>2</sub>S 75963-52-9




orbitoprilum  
orbitopril

(2*S*,3*aS*,7*aS*)-1-[(*S*)-*N*-[(*S*)-1-carboxypentyl]alanyl]hexahydro-2-indoline-carboxylic acid, 1-ethyl ester  
C<sub>20</sub>H<sub>34</sub>N<sub>2</sub>O<sub>5</sub> 108391-88-4




parodilolum  
parodilol

(±)-1-[(2-indol-3-yl-1,1-dimethylethyl)amino]-3-(indol-4-yloxy)-2-propanol  
C<sub>23</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub> 103238-56-8




pelanserinum  
pelanserin

3-[3-(4-phenyl-1-piperazinyl)propyl]-2,4(1*H*,3*H*)-quinazolin-2(1*H*)-one  
C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> 2208-51-7




pimonidazolum  
pimonidazole

(±)-*α*-[(2-nitroimidazol-1-yl)methyl]-1-piperidineethanol  
C<sub>11</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> 70132-50-2




pirtenidinum  
pirtenidine

1,4-dihydro-1-octyl-4-(octylimino)pyridine  
C<sub>21</sub>H<sub>38</sub>N<sub>2</sub> 103923-27-9



pravastatinum  
pravastatin

(+)-(*βR*,*δR*,1*S*,2*S*,6*S*,8*S*,8*aR*)-1,2,6,7,8,8*a*-hexahydro-*β*,*δ*,6,8-tetrahydroxy-2-methyl-1-naphthaleneheptanoic acid, 8-[(2*S*)-2-methylbutyrate]  
C<sub>23</sub>H<sub>36</sub>O<sub>7</sub> 81093-37-0




ramoplaninum  
ramoplanin

factor A<sub>2</sub> of the antibiotic complex A/16686 produced by Actinoplanes sp.  
ATCC 33076  
empirical molecular formula C<sub>119</sub>H<sub>154</sub>ClN<sub>21</sub>O<sub>40</sub>


ranolazinum  
ranolazine

(±)-4-[2-hydroxy-3-(*o*-methoxyphenoxy)propyl]-1-piperazineaceto-2',6'-xylylidide  
C<sub>24</sub>H<sub>33</sub>N<sub>3</sub>O<sub>4</sub> 95635-55-5




retelliptinum  
retelliptine

1-[[3-(diethylamino)propyl]amino]-9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]-  
carbazole  
C<sub>25</sub>H<sub>32</sub>N<sub>4</sub>O 72238-02-9




rilmnidinum  
rilmenidine

2-[(dicyclopropylmethyl)amino]-2-oxazoline  
C<sub>10</sub>H<sub>16</sub>N<sub>2</sub>O 54187-04-1




risperidonum  
risperidone

3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-2-  
methyl-4H-pyrido[1,2-a]pyrimidin-4-one  
C<sub>23</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>2</sub> 106266-06-2




rocastinum  
rocastine

(±)-2-[2-(dimethylamino)ethyl]-3,4-dihydro-4-methylpyrido[3,2-f]-1,4-ox-  
azepine-5(2H)-thione  
C<sub>13</sub>H<sub>19</sub>N<sub>3</sub>OS 91833-77-1




ronactololum  
ronactolol

(±)-4'-[2-hydroxy-3-(isopropylamino)propoxy]-p-anisanilide  
C<sub>20</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub> 90895-85-5




rotraxatum  
rotraxate

*p*-[[*trans*-4-(aminomethyl)cyclohexyl]carbonyl]hydrocinnamic acid  
C<sub>17</sub>H<sub>23</sub>NO<sub>3</sub> 92071-51-7




rufloxacinum  
rufloxacin

9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylic acid  
C<sub>17</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub>S 101363-10-4




seglitidum  
seglitide

cyclo(*N*-methyl-L-alanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-phenylalanyl)  
C<sub>44</sub>H<sub>56</sub>N<sub>8</sub>O<sub>7</sub> 81377-02-8




sibutraminum  
sibutramine

(±)-1-(*p*-chlorophenyl)-*α*-isobutyl-*N,N*-dimethylcyclobutylmethylamine  
C<sub>17</sub>H<sub>26</sub>ClN 106650-56-0



sizofiranum  
sizofiran

Schizophyllan or Poly[3→(O-β-D-glucopyranosyl-(1→3)-O-β-D-glucopyranosyl-(1→6)]-O-β-D-glucopyranosyl-(1→3)-O-β-D-glucopyranosyl)→1]  
(C<sub>24</sub>H<sub>40</sub>O<sub>20</sub>)<sub>n</sub> 9050-67-3




somatorelinum  
somatorelin

growth hormone-releasing factor (human)  
C<sub>215</sub>H<sub>358</sub>N<sub>72</sub>O<sub>66</sub>S 83930-13-6


tameridonum  
tameridone

7-[2-(4-indol-3-ylpiperidino)ethyl]theophylline  
C<sub>22</sub>H<sub>26</sub>N<sub>6</sub>O<sub>2</sub> 102144-78-5




tifuracum  
tifurac

7-[p-(methylthio)benzoyl]-5-benzofuranacetic acid  
C<sub>18</sub>H<sub>14</sub>O<sub>4</sub>S 97483-17-5




tigemonamum  
tigemonam

[[[(Z)-(2-amino-4-thiazolyl)][[(3S)-1-hydroxy-2,2-dimethyl-4-oxo-3-azetidiny]l]carbonyl]methylene]amino]oxy]acetic acid hydrogen sulfate (ester)  
C<sub>12</sub>H<sub>15</sub>N<sub>5</sub>O<sub>9</sub>S<sub>2</sub> 102507-71-1




tilisololum  
tilisolol

(±)-4-[3-(*tert*-butylamino)-2-hydroxypropoxy]-2-methylisocarbostyryl  
C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub> 85136-71-6




tilmicosinum  
tilmicosin

4A-O-de(2,6-dideoxy-3-C-methyl- $\alpha$ -L-ribo-hexopyranosyl)-20-deoxo-20-(*cis*-3,5-dimethylpiperidino)tylosin  
C<sub>46</sub>H<sub>80</sub>N<sub>2</sub>O<sub>13</sub> 108050-54-0




tiospironum  
tiospirone

N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,1-cyclopentanediacet-  
imide  
C<sub>24</sub>H<sub>32</sub>N<sub>4</sub>O<sub>2</sub>S 87691-91-6




tiprotimodum  
tiprotimod

2-[(3-carboxypropyl)thio]-4-methyl-5-thiazoleacetic acid  
C<sub>10</sub>H<sub>13</sub>NO<sub>4</sub>S<sub>2</sub> 105523-37-3



topiramatum  
topiramate

2,3:4,5-di-O-isopropylidene- $\beta$ -D-fructopyranose sulfamate  
C<sub>12</sub>H<sub>21</sub>NO<sub>6</sub>S 97240-79-4




urofollitropinum  
urofollitropin

a preparation of menopausal gonadotrophin extracted from human urine,  
but possessing negligible luteinising hormone (LH) activity


vadocainum  
vadocaine

(±)-6'-methoxy-2-methyl-1-piperidinepropiono-2',4'-xylylide  
 $C_{18}H_{28}N_2O_2$  72005-58-4




vesnarinonum  
vesnarinone

1-(1,2,3,4-tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine  
 $C_{22}H_{25}N_3O_4$  81840-15-5



vinorelbium  
vinorelbine

3',4'-didehydro-4'-deoxy-8'-norvincaleukoblastine  
 $C_{45}H_{54}N_4O_8$  71486-22-1




AMENDMENTS  
TO PREVIOUS LISTS

Supplement to Vol. 32, No. 9, 1978

Proposed International Nonproprietary Names (Prop. INN): List 40

p. 7 cinoquidoxum  
cinoquidox

replace graphic formula by:




Supplement to Vol. 34, No. 9, 1980

Proposed International Nonproprietary Names (Prop. INN): List 44

p. 8 ciadoxum  
ciadox

replace graphic formula by:




Supplement to Vol. 38, No. 2, 1984

Proposed International Nonproprietary Names (Prop. INN): List 51

p. 2 ademetoninum  
ademetonine


replace chemical name, graphic formula and CAS reg. no. by the following:  
(+)-5'-[(R\*)-[(R\*)-3-amino-3-carboxypropyl]methylsulfonio]-5'-deoxy-  
adenosine hydroxide, inner salt  
17176-17-9



Proposed International Nonproprietary Names (Prop. INN): List 55

p. 2     ardacinum  
ardacin

*add the following graphic formula:*



p. 17    tetronasinum  
tetronasin

*replace molecular formula by: C<sub>35</sub>H<sub>54</sub>O<sub>5</sub>*

p. 20    omoconazolium  
omoconazole

*delete 4991 rev. and insert the following CAS reg. no.: 105102-19-0*

**Annex 1**  
**PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL  
NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES\***

The following procedure shall be followed by the World Health Organization in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with the World Health Assembly resolution WHA3.11:

1. Proposals for recommended international nonproprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Nonproprietary Names", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international nonproprietary name is being considered.

A. Such notice shall be given by publication in the *Chronicle of the World Health Organization*<sup>1</sup> and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

- (i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

B. Such notice shall:

- (i) set forth the name under consideration;
- (ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;
- (iii) identify the substance for which a name is being considered;
- (iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;
- (v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.<sup>1</sup>

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.<sup>1</sup>

A. Such objection shall:

- (i) identify the person objecting;
- (ii) state his interest in the name;
- (iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international nonproprietary name.

8. In forwarding a recommended international nonproprietary name to Member States under article 7, the Director-General of the World Health Organization shall:

A. request that it be recognized as the nonproprietary name for the substance; and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

\* Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wild Hlth Org.*, 1955, 60, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wild Hlth Org.*, 1969, 173, 10)

<sup>1</sup> The title of this publication was changed to *WHO Chronicle* in January 1959. From 1967 onwards lists of INNs are published in *WHO Drug Information*.

**GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING  
INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES**

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use.

2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological,

pathological or therapeutic suggestion should be avoided.

*These primary principles are to be implemented by using the following secondary principles*

3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group.

4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. "oxacillin" and "oxacillin sodium", "ibufenac" and "ibufenac sodium".

5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ

only in respect of the name of the inactive acid or the inactive base.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

7. To facilitate the translation and pronunciation of INN, "f" should be

used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y"; the use of the letters "h" and "k" should be avoided.

8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

9. Group relationship in INN (see Guiding Principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use.<sup>1</sup> Where a stem is shown without any hyphens it may be used anywhere in the name.

<i>Latin</i>	<i>English</i>	
-acum	-ac	anti-inflammatory agents of the ibufenac group
-actidum	-actide	synthetic polypeptides with a corticotrophin-like action
-adolum	-adol	} analgesics
-adol-	-adol-	
-astum	-ast	anti-asthmatic, anti-allergic substances not acting primarily as antihistaminics
-astinum	-astine	antihistaminics
-azepamum	-azepam	substances of the diazepam group
-bactamum	-bactam	$\beta$ -lactamase inhibitors
bol	bol	steroids, anabolic
-buzonum	-buzone	anti-inflammatory analgesics of the phenylbutazone group
-cain-	-cain-	antifibrillant substances with local anaesthetic activity
-cainum	-caine	local anaesthetics
cef-	cef-	antibiotics, derivatives of cephalosporanic acid
-cillinum	-cillin	antibiotics, derivatives of 6-aminopenicillanic acid
-conazolium	-conazole	systematic antifungal agents of the miconazole group
cort	cort	corticosteroids, except those of the prednisolone group
-dipinum	-dipine	calcium antagonists of the nifedipine group
-fibratum	-fibrate	substances of the clofibrate group
gest	gest	steroids, progestogens
gli-	gli-	sulfonamide hypoglycemics
io-	io-	iodine-containing contrast media
-ium	-ium	quaternary ammonium compounds
-metacinum	-metacin	anti-inflammatory substances of the indometacin group
-mycinum	-mycin	antibiotics, produced by <i>Streptomyces</i> strains
-nidazolium	-nidazole	antiprotozoal substances of the metronidazole group
-ololum	-olol	$\beta$ -adrenergic blocking agents
-oxacinum	-oxacin	antibacterial agents of the nalidix acid group
-pridum	-pride	sulpiride derivatives
-pril(at)um	pril(at)	angiotensin-converting enzyme inhibitors
-profenum	-profen	anti-inflammatory substances of the ibuprofen group
prost	prost	prostaglandins
-relinum	-relin	hypophyseal hormone release-stimulating peptides
-terolum	-terol	bronchodilators, phenethylamine derivatives
-tidinum	-tidine	H <sub>2</sub> -receptor antagonists
-trexatum	-trexate	folic acid antagonists
-verinum	-verine	spasmolytics with a papaverine-like action
vin-	vin-	} vinca type alkaloids
-vin-	-vin-	

<sup>1</sup> A more extensive listing of stems is contained in the working document Pharm S/Nom 15 which is regularly updated and can be requested from Pharmaceuticals, WHO, Geneva.

**Annex 2**  
**NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES:**  
**TWENTIETH REPORT OF THE WHO EXPERT COMMITTEE**

In its twentieth report<sup>1</sup> the WHO Expert Committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, international nonproprietary names (INN) in the light of developments in pharmaceutical compounds in recent years. The most significant recent change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves employing a characteristic "stem" indicative of a common property of the members of a group. The reasons for, and the implications of, the change are fully discussed. Also

reported is the intention to change the practice with regard to the nomenclature of individual members of polymeric series.

Other sections of the report concern instructions to be followed by bodies making application for international nonproprietary names, the availability of computer-printed cumulative lists of international nonproprietary names, information supplied by WHO Member States concerning their official use of national or international names for pharmaceutical products, and proposals relative to the withdrawal of international nonproprietary names allocated to substances that are no longer in use.

The official texts relating to the procedures for selecting, and general

guidance for devising, international nonproprietary names are reproduced in two annexes to the report. Other annexes give examples of international nonproprietary names that incorporate selected stems, the most frequently used initial groups of letters in international nonproprietary names, a historical review of the programme of selecting international nonproprietary names, some useful literature references, and a model of the form to be used in all applications for international nonproprietary names.

<sup>1</sup> WHO Technical Report Series, No 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances: Twentieth Report of the WHO Expert Committee*), ISBN 92 4 120581 4. Price: Sw. fr. 6.-.